Harnessing more of the immune system for better cancer outcomes
discover onko-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to truly therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
The programs in our pipeline stem from our deep understanding of NK cells and unique screening approaches that exploit their innate anti-tumor biology.
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
